In this Section
205075 SAMHSA - CSAT SBIRT initiative: Cross-site evaluation
Monday, November 9, 2009: 12:30 PM
Recognizing that the treatment needs of both nondependent and dependent populations can best be met through a comprehensive approach to identifying and treating substance use problems across a continuum of severity, the Center for Substance Abuse Treatment (CSAT) within the Substance Abuse and Mental Health Services Administration (SAMHSA) established the Screening, Brief Intervention and Referral to Treatment (SBIRT) program. The SBIRT program represents a major advance in the approach to addressing substance use issues and the role of specialty and healthcare treatment systems. It is important to examine which models of SBIRT may offer the greatest potential to improve the U.S. addiction treatment and heath care systems. To this end, CSAT funded a Cross-Site Evaluation to conduct a multisite evaluation of the effects of SBIRT as implemented in six States and one Tribal Organization.
The SBIRT cross-site infrastructure supports three interrelated evaluation efforts: process, impact/outcome, and economic. The process evaluation serves the critical role of establishing the overall evaluation's context and consequently aids in the interpretation of its findings; it also describes the content of grantees' interventions and their underlying logic models along with their sustainability. The outcome evaluation provides information on what impact the SBIRT interventions have had on the patients, health care practitioners, and grantees and intermediary organizations involved. The outcome evaluation also provides evidence on how specific practitioner and programmatic characteristics relate to effectiveness at the patient and community levels. The economic evaluation provides information on the cost, cost-effectiveness, and cost-benefit of the interventions in Cohort One.
Keywords: Substance Abuse Treatment, Evaluation
Presenting author's disclosure statement:
Qualified on the content I am responsible for because: I have read the APHA policy on full disclosure and I declare that:
I wish to disclose that I have NO financial interests or other relationship with the manufacturers of commercial products, suppliers of commercial services or commercial supporters WITH THE EXCEPTION THAT JBS International, Inc., RTI, Inc., the University of Connecticut, and The Avisa Group and were funded by the Center for Susbstance Abuse Treatment, Substance Abuse and Mental Health Services Administration to be part of a cross-site evaluation team to conduct a cross-site evaluation of CSAT’s SBIRT grantees.
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.